Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | STAT5B | P51692 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5435846 | 1.00 | KDM4E (0.38) | KDM4ERXFP1ALDH1A1LMNAHPGD | |
| Potassium Ion SCHEMBL2476667 | 0.92 | KDM4E (0.37) | KDM4ERXFP1ALDH1A1LMNAHPGD | |
| SCHEMBL4281214 | 0.85 | CYP1A2 (0.39) | KDM4EALDH1A1LMNAHPGDCYP1A2 | |
| SCHEMBL4281222 | 0.85 | CYP1A2 (0.39) | KDM4EALDH1A1LMNAHPGDCYP1A2 | |
| SCHEMBL4281219 | 0.85 | CYP1A2 (0.39) | KDM4EALDH1A1LMNAHPGDCYP1A2 | |
| SCHEMBL5439596 | 0.85 | FBP1 (0.33) | ALDH1A1 | |
| SCHEMBL5439591 | 0.85 | FBP1 (0.33) | ALDH1A1 | |
| SCHEMBL5439602 | 0.85 | FBP1 (0.33) | ALDH1A1 | |
| SCHEMBL1654086 | 0.82 | KDM4E (0.42) | KDM4ERXFP1ALDH1A1LMNAMEN1 | |
| SCHEMBL5571713 | 0.81 | KDM4E (0.41) | KDM4ERXFP1ALDH1A1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1787991-B2 | PYRROLO[2,3-c]PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE | TAKEDA PHARMACEUTICALS CO (JP) | 2020-06-24 | — | — | EP | disclosed |
| US-20180148446-A1 | PYRROLO [2,3-c] PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE | TAKEDA PHARMACEUTICALS CO (JP) | 2018-05-31 | — | — | US | disclosed |
| US-20070293532-A1 | Pyrrolo [2,3-C] Pyridine Compound, Process for Producing the Same, and Use | TAKEDA PHARMACEUTICAL COMPAN6Y LIMITED (JP) | 2007-12-20 | — | — | US | disclosed |
| EP-1787991-A1 | PYRROLOÝ2,3-c¨PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2007-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148446-A1 | PYRROLO [2,3-c] PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE | PGA5, ATP6AP1, PPA1 | KDM4E 686/4885RXFP1 4402/4885ALDH1A1 1988/4885 |
| US-20070293532-A1 | Pyrrolo [2,3-C] Pyridine Compound, Process for Producing the Same, and Use | PGA5, ATP6AP1, PPA1 | KDM4E 686/4885RXFP1 4402/4885ALDH1A1 1988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.